株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

注意欠陥多動性障害(ADHD) - 市場の洞察、疫学、市場予測

Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 602034
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.50円で換算しております。
Back to Top
注意欠陥多動性障害(ADHD) - 市場の洞察、疫学、市場予測 Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2028
出版日: 2019年01月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の注意欠陥多動性障害(ADHD)市場について調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、主要7カ国の市場動向、疫学的予測、アンメットニーズ、治療薬別の市場規模の推移の予測、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 レポート概要

第2章 注意欠陥多動性障害(ADHD)の市場概要

  • 主要7カ国の市場規模(実績値)
  • 主要7カ国の市場規模(予測値)

第3章 疾患背景と概要

  • イントロダクション
  • 原因
  • 病態生理
  • 症状
  • リスク因子
  • 診断

第4章 疫学と患者人口

  • 前提と根拠
  • 主要7カ国の有病数(実数・予測数)
  • 主要7カ国の有病数:年代別(実数・予測数)
  • 診断数と治療可能な症例数(実数・予測数)
  • 疾病の疫学:国別
  • 米国
    • 有病数(実数・予測数)
    • 有病数:年代別(実数・予測数)
    • 治療可能な症例数(実数・予測数)
  • 欧州5カ国
    • ドイツ
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • フランス
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • イタリア
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • スペイン
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
    • 英国
      • 有病数(実数・予測数)
      • 有病数:年代別(実数・予測数)
      • 治療可能な症例数(実数・予測数)
  • 日本
    • 有病数(実数・予測数)
    • 有病数:年代別(実数・予測数)
    • 治療可能な症例数(実数・予測数)

第5章 治療法

  • 治療アルゴリズム
  • 治療ガイドライン

第6章 上市済み薬

  • ストラテラ(Strattera):Eli Lilly
    • 製品説明
    • 作用機序
    • 規制のマイルストーン
    • 開発活動
    • 安全性と有効性
  • ヴィヴァンゼ(Vyvanse):Shire

第7章 新薬

  • キークロスコンテスト
  • Dasotraline:Sunovion
    • 規制のマイルストーン
    • 臨床開発
    • 製品プロファイル
    • 臨床パイプライン活動
  • ND0801:NeuroDerm

第8章 注意欠陥多動性障害(ADHD)市場規模

  • 主な所見
  • 主要7カ国市場の分析
  • 市場概要

第9章 主要7カ国市場の分析:国別

第10章 米国

  • 市場規模
  • 市場規模:治療薬別

第11章 ドイツ

  • 市場規模
  • 市場規模:治療薬別

第12章 フランス

  • 市場規模
  • 市場規模:治療薬別

第13章 英国

  • 市場規模
  • 市場規模:治療薬別

第14章 スペイン

  • 市場規模
  • 市場規模:治療薬別

第15章 イタリア

  • 市場規模
  • 市場規模:治療薬別

第16章 日本

  • 市場規模
  • 市場規模:治療薬別

第17章 市場の成長要因

第18章 市場の障壁

第19章 報告方法論

  • 利用した情報源

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Table 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Table 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Table 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Table 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Table 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Table 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Table 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Table 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Table 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Figure 7: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Figure 17: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Figure 32: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 45: United States-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 51: France-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 60:UK-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Attention-deficit/hyperactivity disorder (ADHD) in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Therapies in USD MM (2016-2028)
目次
Product Code: DIMI0255

DelveInsight's "Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Attention-deficit/hyperactivity disorder (ADHD) epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Attention-deficit/hyperactivity disorder (ADHD) Understanding and Treatment Algorithm

The market report provides the overview of the Attention-deficit/hyperactivity disorder (ADHD) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Attention-deficit/hyperactivity disorder (ADHD) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Attention-deficit/hyperactivity disorder (ADHD) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Attention-deficit/hyperactivity disorder (ADHD) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Attention-deficit/hyperactivity disorder (ADHD) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Attention-deficit/hyperactivity disorder (ADHD) market.

Attention-deficit/hyperactivity disorder (ADHD) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Attention-deficit/hyperactivity disorder (ADHD) Report Insights

  • Patient Population in Attention-deficit/hyperactivity disorder (ADHD)
  • Therapeutic Approaches in Attention-deficit/hyperactivity disorder (ADHD)
  • Attention-deficit/hyperactivity disorder (ADHD) Pipeline Analysis
  • Attention-deficit/hyperactivity disorder (ADHD) Market Size and Trends
  • Attention-deficit/hyperactivity disorder (ADHD) Market Opportunities
  • Impact of upcoming Therapies in Attention-deficit/hyperactivity disorder (ADHD)

Attention-deficit/hyperactivity disorder (ADHD) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Attention-deficit/hyperactivity disorder (ADHD) Report Assessment

  • Current Treatment Practices in Attention-deficit/hyperactivity disorder (ADHD)
  • Unmet Needs in Attention-deficit/hyperactivity disorder (ADHD)
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Attention-deficit/hyperactivity disorder (ADHD) market
  • Organize sales and marketing efforts by identifying the best opportunities for Attention-deficit/hyperactivity disorder (ADHD) market
  • To understand the future market competition in the Attention-deficit/hyperactivity disorder (ADHD) market.

Table of Contents

1. Report Introduction

2. Attention-deficit/hyperactivity disorder (ADHD) Market Overview at a Glance

  • 2.1. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2016
  • 2.2. Market Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2028

3. Disease Background and Overview: Attention-deficit/hyperactivity disorder (ADHD)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM
  • 4.3. Total Prevalent Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM - By Countries

5. Epidemiology of Attention-deficit/hyperactivity disorder (ADHD) by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.1.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.1.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.1.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.1.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.4.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.4.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.4.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.4.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.5.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.5.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.5.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.5.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.6.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.6.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.6.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.6.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.7.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.7.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.7.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.7.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.8.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.8.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.8.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.8.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.9.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.9.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) *
    • 5.9.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
    • 5.9.6. Treatable Cases of the Attention-deficit/hyperactivity disorder (ADHD)

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Attention-deficit/hyperactivity disorder (ADHD)

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Attention-deficit/hyperactivity disorder (ADHD)

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Attention-deficit/hyperactivity disorder (ADHD) : 7MM Market Analysis

  • 12.1. 7MM Market Size of Attention-deficit/hyperactivity disorder (ADHD)
  • 12.2. 7MM Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD)
  • 12.3. 7MM Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products

13. Attention-deficit/hyperactivity disorder (ADHD) : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United States
    • 13.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United States
    • 13.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Germany
      • 13.2.1.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in France
      • 13.2.2.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in France
      • 13.2.2.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Italy
      • 13.2.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Spain
      • 13.2.4.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in United Kingdom
      • 13.2.5.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Attention-deficit/hyperactivity disorder (ADHD) in Japan
    • 13.3.2. Percentage Share of drugs marketed for Attention-deficit/hyperactivity disorder (ADHD) in Japan
    • 13.3.3. Market Sales of Attention-deficit/hyperactivity disorder (ADHD) by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

Back to Top